RxDoctor Payments Data

Bethany Robine, PA

Physician Assistant · Altoona, PANPI 1437404365

Payments from drug & device makers

$9,101in general payments, 2019–2025

Across 87 payments — averaging $104.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Teva Pharmaceuticals USA, Inc.$514
  • E.r. Squibb & Sons, L.L.C.$290
  • Biogen$215
  • Novartis$82
  • Lilly USA, LLC$78
  • plus $179 from 4 others

What the payments were for

  • Consulting fees$1502%
  • Speaking & faculty fees$7,45482%
  • Food & beverage$1,49716%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,101 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$38,810
Medicare patients
70
Services billed
5,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab28$257,353
TysabriNatalizumab16$131,632
Teriflunomide22$104,000
Nurtec OdtRimegepant Sulfate66$101,747
Emgality PenGalcanezumab-Gnlm105$84,897
Aimovig AutoinjectorErenumab-Aooe103$84,015
QuliptaAtogepant60$79,089
NuplazidPimavanserin Tartrate12$58,618
BotoxOnabotulinumtoxina31$36,126
NeuproRotigotine25$21,498
NuedextaDextromethorphan Hbr/Quinidine14$21,364
UbrelvyUbrogepant12$17,646
Lacosamide86$13,200
FycompaPerampanel11$12,335
Levetiracetam307$11,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Botox, Ubrelvy$7,744$132,861103 claims
BiogenTysabri$215$131,63216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Altoona

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →